Quinn Opportunity Partners LLC Boosts Stake in Xencor, Inc. $XNCR

Quinn Opportunity Partners LLC lifted its position in Xencor, Inc. (NASDAQ:XNCR) by 50.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 30,000 shares of the biopharmaceutical company’s stock after acquiring an additional 10,000 shares during the period. Quinn Opportunity Partners LLC’s holdings in Xencor were worth $236,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Braidwell LP grew its position in shares of Xencor by 169.0% in the 1st quarter. Braidwell LP now owns 1,655,690 shares of the biopharmaceutical company’s stock worth $17,617,000 after buying an additional 1,040,159 shares during the period. Primecap Management Co. CA increased its stake in shares of Xencor by 8.6% during the first quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company’s stock valued at $103,857,000 after purchasing an additional 776,580 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in shares of Xencor during the first quarter valued at approximately $4,860,000. BVF Inc. IL boosted its position in shares of Xencor by 19.7% in the 1st quarter. BVF Inc. IL now owns 2,740,141 shares of the biopharmaceutical company’s stock worth $29,155,000 after purchasing an additional 451,381 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its stake in shares of Xencor by 73.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 904,485 shares of the biopharmaceutical company’s stock worth $9,624,000 after buying an additional 384,509 shares during the last quarter.

Xencor Stock Down 3.2%

Xencor stock opened at $14.39 on Thursday. Xencor, Inc. has a 52-week low of $6.92 and a 52-week high of $27.24. The company has a market cap of $1.03 billion, a P/E ratio of -6.00 and a beta of 0.99. The business has a 50-day simple moving average of $12.07 and a two-hundred day simple moving average of $9.76.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.64. The company had revenue of $21.00 million for the quarter, compared to the consensus estimate of $29.73 million. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The firm’s revenue was up 18.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.71) earnings per share. Research analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Royal Bank Of Canada lifted their price objective on Xencor from $18.00 to $19.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Wedbush restated an “outperform” rating and set a $26.00 price target on shares of Xencor in a report on Thursday, November 6th. JPMorgan Chase & Co. lowered their price target on Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Wells Fargo & Company cut their price objective on shares of Xencor from $33.00 to $27.00 and set an “overweight” rating on the stock in a research report on Thursday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a report on Tuesday, October 14th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Xencor presently has a consensus rating of “Moderate Buy” and an average price target of $24.63.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.